PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.80%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 1.27%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-41.28%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 6.48%. Seth Klarman would suspect poor product pricing or inefficient production.
20.03%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.89%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
20.03%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.80%. Joel Greenblatt would see if unique processes drive exceptional profitability.
-89.15%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 13.44%. Seth Klarman would investigate factors dragging net income down.
-78.84%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 16.82%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-78.84%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 16.03%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
3.24%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
3.24%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
47.13%
OCF growth of 47.13% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
28.93%
FCF growth of 28.93% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
-6.49%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 1.88%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-45.05%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-449.35%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
71.41%
5Y OCF/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.47%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
-9039.36%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 29.50%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-781.73%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 44.07%. Seth Klarman might see a fundamental problem if peers maintain growth.
68.70%
5Y net income/share CAGR near Drug Manufacturers - Specialty & Generic median. Charlie Munger might see standard mid-cycle performance in a healthy sector.
88.49%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 31.33%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
7068.67%
Equity/share CAGR of 7068.67% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-27.08%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-0.15%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -3.92%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.16%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-3.39%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-2.72%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-4.57%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -1.25%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-9.02%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
89.29%
R&D growth of 89.29% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
1.66%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.